Athena Countouriotis's Insider Trades & SAST Disclosures
Athena Countouriotis's most recent trade in Iovance Biotherapeutics Inc was a trade of 49,303 Deferred Restricted Stock Unit done . Disclosure was reported to the exchange on June 11, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Athena Countouriotis.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 49,303 | 49,303 | - | - | Deferred Restricted Stock Unit | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 47,693 | 47,693 | - | - | Director Stock Option (right to buy) | |
| Biomarin Pharmaceutical In... | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,720 | 6,900 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 50,000 | - | - | Deferred Restricted Stock Unit | |
| Biomarin Pharmaceutical In... | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2023 | 2,180 | 2,180 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 51,955 | 51,955 | - | - | Deferred Restricted Stock Unit | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 24,000 | 24,000 | - | - | Director Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 24,000 | 24,000 | - | - | Director Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Passage Bio Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 16,918 | 16,918 | - | - | Director Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Athena Countouriotis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges